TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32128615

Group type: EXPERIMENTAL
Intervention: Aprepitant (APR) 125 mg on day 1 and 80 mg on days 2-3
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg (OLN10) on days 1-4
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg (OLN5) on days 1-4
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 35773662

Group type: EXPERIMENTAL
Intervention: Trans-sub-Tenon's anesthesia (ST group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transcutaneous retrobulbar anesthesia (RB group)
Number of subjects: 120
Study: 33561253

Group type: EXPERIMENTAL
Intervention: Calcium (600 mg/d) plus cholecalciferol (200 IU/d) supplementation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 32227368

Group type: EXPERIMENTAL
Intervention: Fluoxetine with cognitive behavioral therapy for 1 year
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo with cognitive behavioral therapy for 1 year
Number of subjects: 93
Study: 35690500

Group type: EXPERIMENTAL
Intervention: ASP3772 (1-, 2-, or 5-µg dose per polysaccharide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV13 (13-valent conjugate vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPSV23 (23-valent polysaccharide vaccine)
Number of subjects: 0
Study: 33032450

Group type: EXPERIMENTAL
Intervention: Left ventricular unloading (using an Impella)
Number of subjects: 686

Group type: COMPARATOR
Intervention: No left ventricular unloading
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Left ventricular unloading
Number of subjects: 686
Study: 34541683

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) 0.3 ml
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (open palatal wound after FGG harvest)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 44
Study: 35263746

Group type: EXPERIMENTAL
Intervention: EMiC®2‐CVVHD
Number of subjects: 20

Group type: COMPARATOR
Intervention: AV1000S®‐CVVHDF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both modalities
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 20
Study: 32702689

Group type: EXPERIMENTAL
Intervention: Right hand‐assisted laparoscopic donor nephrectomy (R‐HALDN)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Left hand‐assisted laparoscopic donor nephrectomy (L‐HALDN)
Number of subjects: 270
Study: 35288086

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33732434

Group type: EXPERIMENTAL
Intervention: Intranasal esketamine (56mg) administered twice a week for four consecutive weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo administered twice a week for four consecutive weeks
Number of subjects: 120
Study: 32858573

Group type: EXPERIMENTAL
Intervention: Nadroparin calcium-warfarin sequential (NWS) therapy (1-month nadroparin calcium by subcutaneous injection followed by 5-month warfarin by oral administration)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no anticoagulation therapy)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: NWS anticoagulation therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: NWS therapy group
Number of subjects: 64
Study: 35090535

Group type: EXPERIMENTAL
Intervention: IV lidocaine infusion (2% lidocaine) for 6–12 hours starting at the beginning of surgery
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo infusion for 6–12 hours starting at the beginning of surgery
Number of subjects: 562
Study: 34258469

Group type: EXPERIMENTAL
Intervention: TOTAL intervention (18-min video highlighting obesity health risks and treatment outcomes)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study: 36007302

Group type: EXPERIMENTAL
Intervention: HEPA filter air cleaners
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (no air cleaners)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Indoor PM2.5 concentrations during pregnancy
Number of subjects: 540
Study: 33682693

Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension (KTT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kinesio Taping no tension (KTNT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: KTT and KTNT
Number of subjects: 60
Study: 33090921

Group type: EXPERIMENTAL
Intervention: PRC-063 (methylphenidate), 25 mg/day titrated to maximum 85 mg/day
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: PRC-063 (methylphenidate)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 35412603

Group type: EXPERIMENTAL
Intervention: Vi‐tetanus toxoid TCV
Number of subjects: 61654

Group type: EXPERIMENTAL
Intervention: Better WASH households
Number of subjects: 61654

Group type: EXPERIMENTAL
Intervention: Better WASH in TCV clusters
Number of subjects: 61654

Group type: COMPARATOR
Intervention: Japanese Encephalitis (JE) vaccine
Number of subjects: 61654
Study: 33118456

Group type: EXPERIMENTAL
Intervention: Potentially identifiable interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anonymous survey
Number of subjects: 0
Study: 32273094

Group type: EXPERIMENTAL
Intervention: COMBO stent
Number of subjects: 862

Group type: COMPARATOR
Intervention: Orsiro stent
Number of subjects: 862
Study: 35333027

Group type: EXPERIMENTAL
Intervention: FIVE program (neuromuscular warm-up) performed in addition to regular futsal training, three times per week for 6 weeks.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Regular futsal training only (Control group).
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: FIVE program (experimental group).
Number of subjects: 95
Study: 34357593

Group type: EXPERIMENTAL
Intervention: BBT‐CI intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: HEAL control intervention
Number of subjects: 139
Study: 35488487

Group type: EXPERIMENTAL
Intervention: Brand metoprolol ER tablets
Number of subjects: 36

Group type: COMPARATOR
Intervention: Drug 1 (generic metoprolol ER)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Drug 2 (generic metoprolol ER)
Number of subjects: 36
Study: 33755713

Group type: EXPERIMENTAL
Intervention: GSK2618960 (0.6 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GSK2618960 (2.0 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GSK2618960
Number of subjects: 11
Study: 35595658

Group type: EXPERIMENTAL
Intervention: Durvalumab in addition to anthracycline taxane-based neoadjuvant therapy
Number of subjects: 82
Study: 32710212

Group type: EXPERIMENTAL
Intervention: PTE-RV
Number of subjects: 84
Study: 37103755

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 161
Study: 32933342

Group type: EXPERIMENTAL
Intervention: Electronic medical record-based methods
Number of subjects: 294

Group type: COMPARATOR
Intervention: Non-electronic medical record-based methods
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Patient portal messaging
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Direct mail to non-active patient portal
Number of subjects: 294
Study: 35788493

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 270

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 270
Study: 34410254

Group type: EXPERIMENTAL
Intervention: Proprioception training twice a week for eight weeks along with diabetes awareness lectures once a week
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group receiving only diabetes awareness lectures
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Proprioception training
Number of subjects: 38
Study: 36095058

Group type: EXPERIMENTAL
Intervention: Self-efficacy for physical activity with perceived facilitators (24 items retained)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-efficacy to overcome barriers (28 items retained)
Number of subjects: 0
Study: 34922527

Group type: EXPERIMENTAL
Intervention: Individualized and detailed multivariate method based on Caries Care International 4D guidelines
Number of subjects: 2

Group type: COMPARATOR
Intervention: Simplified method based on caries experience evaluation using the DMFT/dmft index
Number of subjects: 2
Study: 32060017

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (dietary weight loss)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nondiabetic control (NDC) group
Number of subjects: 39
Study: 35190406

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) transfusion on days 0 and 7
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline) on days 0 and 7
Number of subjects: 100
Study: 33725471

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interactive education intervention
Number of subjects: 0
Study: 32650988

Group type: EXPERIMENTAL
Intervention: cfDNA extraction using QIAamp Circulating Nucleic Acid Extraction Kit (Qiagen)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oncomine Breast cfDNA Assay (A31183) and custom Ampliseq Ion Torrent panel targeting breast cancer-related genes
Number of subjects: 52
Study: 33196110

Group type: EXPERIMENTAL
Intervention: Magnetic needle-tracking ultrasound device (MUD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional ultrasonography device (CUD)
Number of subjects: 50
Study: 32207209

Group type: EXPERIMENTAL
Intervention: BFR+ (Biofermin-R) with VPZ-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: BFR- (no Biofermin-R) with VPZ-based therapy
Number of subjects: 0
Study: 34861776

Group type: EXPERIMENTAL
Intervention: UMPCNL in FFMS position
Number of subjects: 55

Group type: COMPARATOR
Intervention: UMPCNL in prone position
Number of subjects: 55
Study: 34003690

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3014
Study: 35348950

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 119

Group type: COMPARATOR
Intervention: No letrozole (Control)
Number of subjects: 119
Study: 34479646

Group type: EXPERIMENTAL
Intervention: Coordinated care program (SOFIA model)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 33849123

Group type: EXPERIMENTAL
Intervention: Infection prevention group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 128
Study: 35060833

Group type: EXPERIMENTAL
Intervention: Risk score based on identified factors
Number of subjects: 1313
Study: 34505186

Group type: EXPERIMENTAL
Intervention: Cannabidiol and delta‐9‐tetrahydrocannabinol
Number of subjects: 3
Study: 33407264

Group type: EXPERIMENTAL
Intervention: Botulinum toxin bilateral medial rectus injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 60
Study: 32762424

Group type: EXPERIMENTAL
Intervention: Self-persuasion task (participants generate own arguments or arguments they think the close other would give)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Direct persuasion task (participants read given arguments or imagine arguments from the close other)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Thinking of a close other
Number of subjects: 987
Study: 34821127

Group type: EXPERIMENTAL
Intervention: Majoon-e-Seer Alvi Khan (MSAK) for 60 days along with lifestyle modification
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tablet Atorvastatin for 60 days along with lifestyle modification
Number of subjects: 40
Study: 35869710

Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block (TPVB) before general anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia
Number of subjects: 80
Study: 36402600

Group type: EXPERIMENTAL
Intervention: Animation
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control
Number of subjects: 183
Study: 33864887

Group type: EXPERIMENTAL
Intervention: Papacarie for 60s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carisolv for 60s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% NaOCl for 15s
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 40
Study: 33802311

Group type: EXPERIMENTAL
Intervention: Healthy Mind program (eMH intervention) for eight weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention during the eight weeks)
Number of subjects: 150
Study: 32930387

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + nintedanib (F + N) (2 × 200 mg p.o./d, d1‐d14)
Number of subjects: 53

Group type: COMPARATOR
Intervention: mFOLFOX6 + placebo (F + P)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + nintedanib (F + N)
Number of subjects: 53
Study: 36343061

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) model using one knee magnetic resonance image
Number of subjects: 164
Study: 32221989

Group type: EXPERIMENTAL
Intervention: CBT + ICT
Number of subjects: 60

Group type: COMPARATOR
Intervention: CBT + sham training
Number of subjects: 60
Study: 34776351

Group type: EXPERIMENTAL
Intervention: Brief focused ultrasound of ventricular filling and function, lung, and peritoneal spaces, performed before surgery.
Number of subjects: 660
Study: 33185570

Group type: EXPERIMENTAL
Intervention: Neutral hand-off
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rude hand-off
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Neutral hand-off (Residents)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Rude hand-off (Residents)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Experience (Residents)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Experience (Fellows)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Experience (Attendings)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Experience
Number of subjects: 41
Study: 33883459

Group type: EXPERIMENTAL
Intervention: Visual airway cognitive aid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no visual airway cognitive aid)
Number of subjects: 40
Study: 34879921

Group type: EXPERIMENTAL
Intervention: Hyperthermia exposure programme (WBPH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham exposure (SHAM)
Number of subjects: 20
Study: 33080294

Group type: EXPERIMENTAL
Intervention: internet-based mindfulness-based stress reduction course (IMMI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: internet-based health and wellness education course
Number of subjects: 64

Group type: COMPARATOR
Intervention: waitlist control condition
Number of subjects: 64
Study: 37610062

Group type: COMPARATOR
Intervention: Imeglimin monotherapy at 1,000 mg twice daily
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Imeglimin monotherapy at 1,500 mg
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Imeglimin monotherapy at 2,000 mg
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Imeglimin adjunctive therapy at 1,000 mg
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Imeglimin adjunctive therapy at 1,500 mg
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Imeglimin (monotherapy and adjunctive therapy)
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1655
Study: 32900519

Group type: EXPERIMENTAL
Intervention: 75 mg trans-resveratrol twice-daily for 12 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 32739494

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 36054038

Group type: EXPERIMENTAL
Intervention: Edaravone treatment after placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Edaravone treatment
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 146
Study: 32077301

Group type: EXPERIMENTAL
Intervention: Self-weighing-only programs
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Programs with financial incentives
Number of subjects: 498
Study: 34823128

Group type: EXPERIMENTAL
Intervention: Influence-gain nudge
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Comparison nudge
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Influence-loss nudge
Number of subjects: 1595

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1595
Study: 34085363

Group type: EXPERIMENTAL
Intervention: Blood group A
Number of subjects: 72

Group type: COMPARATOR
Intervention: Blood group O
Number of subjects: 72

Group type: COMPARATOR
Intervention: Blood group A vs O
Number of subjects: 72
Study: 33974574

Group type: EXPERIMENTAL
Intervention: Increased compression factor (1.75 D)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional compression factor (0.75 D)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both compression factors
Number of subjects: 44
Study: 34773302

Group type: EXPERIMENTAL
Intervention: Combined photodynamic therapy (combPDT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (cPDT)
Number of subjects: 51
Study: 33693737

Group type: EXPERIMENTAL
Intervention: β-Lactoglobulin (BLG)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Whey Protein (WHE)
Number of subjects: 9
Study: 32812363

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal direct current stimulation (tsDCS) at 2.5 mA for 10 min
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham transcutaneous spinal direct current stimulation (sham tsDCS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal direct current stimulation (tsDCS)
Number of subjects: 41
Study: 35471471

Group type: EXPERIMENTAL
Intervention: Low-dose Lingguizhugan Decoction (LGZG)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Standard-dose Lingguizhugan Decoction (LGZG)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 34939395

Group type: EXPERIMENTAL
Intervention: Shumian capsule
Number of subjects: 200

Group type: COMPARATOR
Intervention: Shumian capsule simulator (control)
Number of subjects: 200
Study: 34963728

Group type: EXPERIMENTAL
Intervention: Protocolized weaning using pressure support spontaneous breathing trial (PS SBT) for 2 hours duration followed by a T-piece trial before extubation.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Protocolized weaning using PS SBT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional weaning with synchronized intermittent mandatory ventilation mode and a T-piece trial before extubation.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional weaning
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (reintubated patients)
Number of subjects: 80
Study: 32212275

Group type: EXPERIMENTAL
Intervention: TransCon PTH (3.5 to 124 μg PTH(1‐34) for SAD; 3.5 to 24 μg PTH(1‐34)/day for MAD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TransCon PTH
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TransCon PTH (administered daily for 10 days)
Number of subjects: 10
Study: 35353292

Group type: EXPERIMENTAL
Intervention: continuous Theta Burst Stimulation (cTBS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo stimulation
Number of subjects: 35
Study: 34098302

Group type: EXPERIMENTAL
Intervention: Real-time video counselling
Number of subjects: 655

Group type: COMPARATOR
Intervention: Telephone counselling
Number of subjects: 655

Group type: COMPARATOR
Intervention: Minimal intervention control (written materials)
Number of subjects: 655
Study: 33168489

Group type: COMPARATOR
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with W-water (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with CHX-2% digluconate chlorhexidine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with E64-5 μM E64
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with ACD-W
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with ERO-W
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with ACD-CHX
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with ACD-E64
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with ERO-CHX
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adper Single Bond Universal (Etch‐and‐rinse mode)/Filtek Z250 with ERO-E64
Number of subjects: 90
Study: 32524330

Group type: EXPERIMENTAL
Intervention: Proactive assessment of familial breast cancer risk using a validated postal family history questionnaire and decision support software.
Number of subjects: 7012

Group type: EXPERIMENTAL
Intervention: Referral to specialists for further assessment.
Number of subjects: 7012

Group type: COMPARATOR
Intervention: Usual care without proactive assessment.
Number of subjects: 7012
Study: 36457200

Group type: EXPERIMENTAL
Intervention: Polymicrobial probiotic (PMP group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Mono-strain probiotic (MSP group)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study: 32885276

Group type: EXPERIMENTAL
Intervention: Midodrine (20 mg orally every 8 hours)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (oral every 8 hours)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Midodrine (20 mg)
Number of subjects: 136
Study: 33065954

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (54 to 64 U)
Number of subjects: 139
Study: 36497618

Group type: EXPERIMENTAL
Intervention: SHIFT intervention for drivers with obesity (BMI ≥ 30 kg/m2)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group for drivers with obesity (BMI ≥ 30 kg/m2)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: SHIFT intervention for drivers without obesity (BMI < 30 kg/m2)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group for drivers without obesity (BMI < 30 kg/m2)
Number of subjects: 244
Study: 33756024

Group type: EXPERIMENTAL
Intervention: Simplified Chinese Nonrestorative Sleep Scale (NRSS)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis (CFA) of NRSS
Number of subjects: 486
Study: 36178197

Group type: EXPERIMENTAL
Intervention: Bexagliflozin 20 mg
Number of subjects: 426

Group type: COMPARATOR
Intervention: Glimepiride (control)
Number of subjects: 426